Form 4 for FTH Faeth Therapeutics, Inc.
Accepted 2024-02-16 00:00:00 ET · period of report 2024-02-15 · accession 0001415889-24-004235 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-16 | 2024-02-15 | FTH | Celebi John | Pres AND CEO, Dir | F - Tax | $0.79 | -5,891 | 105.4K | -5% | -$4,654 |
| DM | 2024-02-16 | 2024-02-15 | FTH | Celebi John | Pres AND CEO, Dir | A - Grant | $0.00 | +480.9K | 165.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-15 | F | D | 5,891 | $0.79 | 105,420 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-02-15 | A | A | 315,000 | $0.00 | 315,000 | D | $0.79 · — to 2034-02-14 | 315,000 Common Stock | (F2) The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2025, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-02-15 | A | A | 165,889 | $0.00 | 165,889 | D | $0.79 · — to 2034-02-14 | 165,889 Common Stock | (F3) Represents one-third of the Reporting Person's 2023 annual bonus, which the Compensation Committee of the Issuer determined to pay in the form of a stock option in lieu of cash. 100% of the shares are fully vested as of the date of grant. |